Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of RO7496353 with checkpoint inhibitor ± chemotherapy in advanced solid tumors
jRCT2031230222Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ro7496353 in Non-hematologic malignancy (4 arms), sponsored by Genentech. Primary endpoints: Safety and tolerability of RO7496353 combinations and Pharmacokinetics of RO7496353. Started Oct 2023; status: completed.
02
Drugs
ro7496353
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031230222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230222.